Abstract
Hybridoma technology has now advanced to the point where hundreds of monoclonal antibodies have been produced and are reported to bind to normal and malignant cell surfaces or intracellular organelles. The original hope for tumor-specific antigens has not materialized, but certain antibodies with rather restricted ranges of binding activities have been identified. This panel discusses the use of such monoclonal antibodies in diagnosis, prognosis, and treatment of human breast disease and breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Additional information
A series of teleconferences has been organized under the auspices of Mead Johnson to address several major current questions in oncology. A panel of recognized experts with a moderator has been assembled to discuss each question, and we will report a number of these discussions in this and succeeding issues of Breast Cancer Research and Treatment. This is reprinted from ‘Oncology Viewpoints’, courtesy of Mead Johnson Oncology Division, Evansville IN 47721, USA.
Rights and permissions
About this article
Cite this article
McGuire, W.L., Ceriani, R.L., Schlom, J. et al. Monoclonal antibodies, benign breast disease, and breast cancer. Breast Cancer Res Tr 6, 37–47 (1985). https://doi.org/10.1007/BF01806009
Issue Date:
DOI: https://doi.org/10.1007/BF01806009